JPH04305519A - Skin humectant for external use - Google Patents
Skin humectant for external useInfo
- Publication number
- JPH04305519A JPH04305519A JP3147013A JP14701391A JPH04305519A JP H04305519 A JPH04305519 A JP H04305519A JP 3147013 A JP3147013 A JP 3147013A JP 14701391 A JP14701391 A JP 14701391A JP H04305519 A JPH04305519 A JP H04305519A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- extract
- saffron
- stigma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003906 humectant Substances 0.000 title abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000001599 crocus sativus l. flower extract Substances 0.000 claims description 14
- 229940076591 saffron extract Drugs 0.000 claims description 14
- 239000004909 Moisturizer Substances 0.000 claims description 6
- 230000001333 moisturizer Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 15
- 239000000284 extract Substances 0.000 abstract description 10
- 244000124209 Crocus sativus Species 0.000 abstract description 8
- 235000015655 Crocus sativus Nutrition 0.000 abstract description 8
- 235000013974 saffron Nutrition 0.000 abstract description 8
- 239000004248 saffron Substances 0.000 abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 229940058015 1,3-butylene glycol Drugs 0.000 abstract 1
- 235000019437 butane-1,3-diol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 description 13
- 239000006210 lotion Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003974 emollient agent Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- -1 etc.) Substances 0.000 description 5
- 235000015961 tonic Nutrition 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- UYZQWKKNVBJVOF-UHFFFAOYSA-N 1-decoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCC UYZQWKKNVBJVOF-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- PXGPQCBSBQOPLZ-UHFFFAOYSA-N butanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCC(O)=O PXGPQCBSBQOPLZ-UHFFFAOYSA-N 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は、サフラン抽出物を有効
成分とする皮膚外用保湿剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a moisturizer for external use on the skin containing saffron extract as an active ingredient.
【0002】0002
【従来の技術】化粧料、医薬品などの皮膚外用剤の中に
は皮膚の保湿効果を高めることを目的としているものが
数多く見受けられる。これらは、正常な皮膚保湿性を保
つことや、乾燥や洗剤使用による肌荒れによる保湿能力
の低下を補うことを目的にしている。これまで、保湿効
果を有するものとして、グリセリン、プロピレングリコ
ール、ソルビトールなどの多価アルコール、ヒアルロン
酸、コンドロイチン硫酸などの動物抽出物質などが使用
されていた。一方、サフランは内服薬として月経不順、
冷え性などの婦人用薬や保健薬に使用されているほか、
近年、抗血液凝固作用などが報告されているが、その抽
出物の保湿作用、特に皮膚外用剤における保湿作用につ
いてはこれまで知られていない。BACKGROUND OF THE INVENTION Many external skin preparations such as cosmetics and pharmaceuticals are intended to enhance the moisturizing effect of the skin. The purpose of these products is to maintain normal skin moisturizing properties and to compensate for the decline in moisturizing ability caused by dryness or rough skin caused by detergent use. So far, polyhydric alcohols such as glycerin, propylene glycol, and sorbitol, and animal extracts such as hyaluronic acid and chondroitin sulfate have been used as substances with moisturizing effects. On the other hand, saffron can be used as an oral medicine to treat menstrual irregularities.
In addition to being used in women's medicines and health medicines for treating sensitivity to cold,
In recent years, anti-blood coagulation effects have been reported, but the moisturizing effect of the extract, particularly in external skin preparations, has not been known so far.
【0003】0003
【発明が解決しようとする課題】従来用いられていた保
湿剤には次のような欠点があった。例えば、多価アルコ
ール類では使用感の面でベタツキがあり、効果的な濃度
を製剤中に配合することは困難であった。また、動物抽
出物質は高価である一方、高分子物質であることから経
皮吸収性が悪く、十分満足できるものとは言えなかった
。[Problems to be Solved by the Invention] Conventionally used humectants have the following drawbacks. For example, polyhydric alcohols have a sticky feel when used, and it has been difficult to incorporate them into formulations at an effective concentration. In addition, animal extracts are expensive, and because they are polymeric substances, they have poor percutaneous absorption, and cannot be said to be fully satisfactory.
【0004】0004
【課題を解決するための手段】そこで、本発明者らは、
効果はもちろん、安全性や使用感など全ての面で優れた
保湿剤を開発すべく、主に植物抽出物について研究を行
った結果、サフラン抽出物に優れた保湿作用があること
を発見し、本発明を完成した。すなわち、本発明はサフ
ラン抽出物を有効成分とする皮膚外用保湿剤である。本
発明において、サフラン抽出物とは、サフランの柱頭,
花柱上部の成分を抽出したものを指し、その調製方法と
しては例えばサフランの柱頭及び花柱上部を乾燥したも
のに溶媒(例えば、水、30〜70重量%のエタノール
水溶液、エタノール、プロピレングリコール、1,3−
ブチレングリコール、イソプロパノールなど)を加え、
室温で数日間(例えば、5〜8日間)抽出した液をろ過
して調製すればよい。[Means for solving the problem] Therefore, the present inventors
In order to develop a moisturizer that is excellent in all aspects, including effectiveness, safety, and usability, we conducted research mainly on plant extracts, and discovered that saffron extract has excellent moisturizing effects. The invention has been completed. That is, the present invention is an external skin moisturizer containing saffron extract as an active ingredient. In the present invention, saffron extract refers to saffron stigma,
It refers to the extracted components of the upper part of the style, and its preparation method includes, for example, drying the stigma and upper part of the style of saffron and adding a solvent (e.g., water, 30 to 70% by weight aqueous ethanol solution, ethanol, propylene glycol, 3-
butylene glycol, isopropanol, etc.)
It may be prepared by filtering a liquid extracted at room temperature for several days (for example, 5 to 8 days).
【0005】前記サフラン抽出物の配合量は、例えばサ
フランの柱頭100gに30%エタノール水溶液200
mlを加え、室温で5日間放置した液を濾過して製した
場合、製剤全量に対して0.1〜5重量%である。[0005] The blending amount of the saffron extract is, for example, 200 g of a 30% ethanol aqueous solution per 100 g of saffron stigma.
ml and left at room temperature for 5 days and then filtered, the amount is 0.1 to 5% by weight based on the total amount of the preparation.
【0006】本発明の皮膚外用保湿剤は、クレンジング
クリーム、クレンジングローション、石鹸などの洗浄剤
、各種化粧水、エモリエントクリーム、マッサージクリ
ーム、サンスクリーンクリーム、リップクリームなどの
クリーム剤、エモリエントローション、モイスチュアロ
ーション、ミルキィローション、ナリシングローション
、マッサージローションなどのローション・乳液類、ヘ
アトニック、養毛剤、整髪料などの頭髪用剤、角質軟化
剤、抗真菌剤(いわゆる水虫治療剤)、にきび治療剤、
抗炎症剤(ステロイド外用剤)などに配合してヒトの皮
膚に適用することができる。また、製剤の目的によって
、副腎皮質ホルモン(例えば、酢酸ヒドロコルチゾン、
酪酸プロピオン酸ヒドロニルチゾン)、抗ヒスタミン剤
(例えば、塩酸ジフェンヒドラミン、塩酸イソチベンジ
ルなど)、局所麻酔剤(例えば、塩酸ジブカイン、塩酸
リドカインなど)、末梢血管拡張剤(例えば、ビタミン
Eアセテート、ニコチン酸ベンジル、オタネニンジンエ
キス、センブリ抽出エキス、トウガラシチンキ、塩化カ
ルプロニウム、ミノキシジルなど)、抗炎症剤(例えば
、グリチルレチン酸、グアイアズレンなど)、角質溶解
剤(例えば、尿素、サリチル酸など)、殺菌剤(例えば
、グルコン酸クロルヘキシジン、イソプロピルメチルフ
ェノール、第4級アンモニウム塩、ヒノキチオールなど
)、抗真菌剤(例えば、クリトリマゾール、硝酸ミコナ
ゾールなど)などを本発明の効果を損なわない範囲で配
合することができる。[0006] The external skin moisturizer of the present invention includes cleansing creams, cleansing lotions, detergents such as soaps, various lotions, creams such as emollient creams, massage creams, sunscreen creams, and lip balms, emollient lotions, and moisturizing lotions. , lotions and emulsions such as milky lotion, nourishing lotion, and massage lotion, hair preparations such as hair tonics, hair tonics, and hair conditioners, keratin softeners, antifungal agents (so-called athlete's foot treatment agents), acne treatment agents,
It can be combined with anti-inflammatory drugs (topical steroids) and applied to human skin. Depending on the purpose of the preparation, adrenocortical hormones (e.g., hydrocortisone acetate,
hydronyltisone propionate butyrate), antihistamines (e.g., diphenhydramine hydrochloride, isotibenzyl hydrochloride, etc.), local anesthetics (e.g., dibucaine hydrochloride, lidocaine hydrochloride, etc.), peripheral vasodilators (e.g., vitamin E acetate, benzyl nicotinate, Panax ginseng extract) , Jasperia japonica extract, capsicum tincture, carpronium chloride, minoxidil, etc.), anti-inflammatory agents (e.g., glycyrrhetinic acid, guaiazulene, etc.), keratolytic agents (e.g., urea, salicylic acid, etc.), bactericidal agents (e.g., chlorhexidine gluconate, isopropyl Methylphenol, quaternary ammonium salts, hinokitiol, etc.), antifungal agents (for example, clitorimazole, miconazole nitrate, etc.), etc. can be blended within a range that does not impair the effects of the present invention.
【0007】本発明の皮膚外用保湿剤は、1日に数回(
好ましくは2〜3回)、適量を皮膚に塗布する。[0007] The skin external moisturizer of the present invention can be used several times a day (
Apply an appropriate amount to the skin (preferably 2 to 3 times).
【0008】[0008]
【発明の効果】本発明により、効果、使用感共に優れた
保湿剤を提供することが可能になった。[Effects of the Invention] According to the present invention, it has become possible to provide a moisturizing agent that is excellent in both effectiveness and usability.
【0009】[0009]
【実施例】以下、実施例及び試験例を挙げて本発明を更
に具体的に説明する。なお、実施例及び試験例で使用し
たサフラン抽出物は、サフランの柱頭100gに30%
エタノール水溶液200mlを加え、室温で5日間放置
した液を濾過して製したものである。
実施例1(クレンジングクリーム)
パラフィン5重量部、セタノール1.5重量部、流動パ
ラフィン28重量部、ワセリン18重量部、モノステア
リン酸グリセリン3重量部、ポリオキシエチレン(20
)モノラウリン酸エステル3重量部を加熱しながら撹拌
して溶解した。あらかじめサフラン抽出物0.2重量部
、プロピレングリコール2重量部、パラオキシ安息香酸
エチル0.1重量部、精製水39.2重量部を加熱しな
がら撹拌して溶解した液を前記溶液に加え、撹拌乳化し
てクレンジングクリームを調製した。[Examples] The present invention will be explained in more detail below with reference to Examples and Test Examples. The saffron extract used in the Examples and Test Examples was 30% per 100g of saffron stigma.
It was prepared by adding 200 ml of an aqueous ethanol solution and letting the solution stand at room temperature for 5 days, then filtering the solution. Example 1 (Cleansing Cream) 5 parts by weight of paraffin, 1.5 parts by weight of cetanol, 28 parts by weight of liquid paraffin, 18 parts by weight of petrolatum, 3 parts by weight of glyceryl monostearate, polyoxyethylene (20 parts by weight)
) 3 parts by weight of monolaurate were dissolved by stirring while heating. 0.2 parts by weight of saffron extract, 2 parts by weight of propylene glycol, 0.1 parts by weight of ethyl paraoxybenzoate, and 39.2 parts by weight of purified water were dissolved in advance by stirring while heating, and a solution was added to the solution, and the mixture was stirred. A cleansing cream was prepared by emulsification.
【0010】実施例2(エモリエントクリーム)グリセ
リンモノステアレート2重量部、ポリオキシエチレン(
20)ソルビタンモノラウリン酸エステル2重量部、ミ
ツロウ6重量部、セタノール5重量部、還元ラノリン8
重量部、スクワラン35.3重量部、セチルアルコール
2重量部、ステアリルアルコール2重量部、ビタミンE
アセテート0.2重量部を加熱しながら撹拌して溶解し
た。あらかじめ、サフラン抽出物0.5重量部、エデト
酸4ナトリウム、0.05重量部、ジブチルヒドロキシ
トルエン0.05重量部、精製水36.9重量部を加熱
して撹拌溶解した液を前記溶液に加え、撹拌、乳化して
エモリエントクリームを調製した。Example 2 (emollient cream) 2 parts by weight of glycerin monostearate, polyoxyethylene (
20) Sorbitan monolaurate 2 parts by weight, beeswax 6 parts by weight, cetanol 5 parts by weight, reduced lanolin 8 parts by weight
Parts by weight, squalane 35.3 parts by weight, cetyl alcohol 2 parts by weight, stearyl alcohol 2 parts by weight, vitamin E
0.2 parts by weight of acetate was stirred and dissolved while heating. In advance, 0.5 parts by weight of saffron extract, 0.05 parts by weight of tetrasodium edetate, 0.05 parts by weight of dibutylhydroxytoluene, and 36.9 parts by weight of purified water were heated and dissolved with stirring, and then added to the above solution. The mixture was added, stirred, and emulsified to prepare an emollient cream.
【0011】実施例3(エモリエントローション)エタ
ノール15重量部にパラオキシ安息香酸エチル0.1重
量部、ポリオキシエチレン(20)ソルビタンモノラウ
リン酸エステル1.5重量部、オレイルアルコール0.
1重量部、サフラン抽出物0.3重量部、コウジ酸0.
1重量部、ビタミンCリン酸エステルマグネシウム塩0
.2重量部、エテト酸4ナトリウム0.05重量部、ジ
ブチルヒドロキシトルエン0.05重量部を加えて溶か
し、精製水82.6重量部を加えて均一とし、エモリエ
ントローションを調製した。Example 3 (emollient lotion) 15 parts by weight of ethanol, 0.1 part by weight of ethyl paraoxybenzoate, 1.5 parts by weight of polyoxyethylene (20) sorbitan monolaurate, 0.0 parts by weight of oleyl alcohol.
1 part by weight, 0.3 parts by weight of saffron extract, 0.0 parts by weight of kojic acid.
1 part by weight, vitamin C phosphate ester magnesium salt 0
.. 2 parts by weight, 0.05 parts by weight of tetrasodium etetate, and 0.05 parts by weight of dibutylhydroxytoluene were added and dissolved, and 82.6 parts by weight of purified water was added to make the mixture homogeneous to prepare an emollient lotion.
【0012】実施例4(皮膚炎群用軟膏)ステアリルア
ルコール3重量部、サラシミツロウ8重量部、白色ワセ
リン70重量部を加熱、融解して混合し、これにコレス
テロール3重量部を加えて溶解した。加熱をやめ、かき
まぜながら冷却した後、あらかじめ白色ワセリン13.
6重量部とサフラン抽出物0.1重量部、酢酸ヒドロコ
ルチゾン0.1重量部、塩酸ジフェンヒドラミン1重量
部、塩酸クロルヘキシジン0.1重量部、ビタミンEア
セテート0.1重量部、ソルビタンモノオレイン酸エス
テル1重量部を均一に混合したものを加え、均一になる
までかき混ぜ、油性軟膏剤を調製した。Example 4 (Ointment for dermatitis) 3 parts by weight of stearyl alcohol, 8 parts by weight of white beeswax, and 70 parts by weight of white petrolatum were heated and melted and mixed, and 3 parts by weight of cholesterol was added and dissolved. . After stopping heating and cooling while stirring, add white petrolatum 13.
6 parts by weight, 0.1 part by weight of saffron extract, 0.1 part by weight of hydrocortisone acetate, 1 part by weight of diphenhydramine hydrochloride, 0.1 part by weight of chlorhexidine hydrochloride, 0.1 part by weight of vitamin E acetate, 1 part by weight of sorbitan monooleate. A homogeneous mixture of parts by weight was added and stirred until homogeneous to prepare an oily ointment.
【0013】実施例5(養毛トニック)センブリエキス
3重量部、ヒノキチオール0.2重量部、β−エストラ
ジオール0.0008重量部、ビタミンEアセテート0
.2重量部、1−メントール0.5重量部、サフラン抽
出物1重量部、エタノール55重量部、ポリオキシエチ
レン(20)ポリオキシプロピレン(6)デシルテトラ
デシルエーテル2重量部、エテト酸4ナトリウム0.0
5重量部、ジブチルヒドロキシトルエン0.05重量部
、精製水37.9992重量部を混合、溶解し、トニッ
クタイプの養毛剤を調製した。Example 5 (hair nourishing tonic) 3 parts by weight of Oriental japonica extract, 0.2 parts by weight of hinokitiol, 0.0008 parts by weight of β-estradiol, 0 parts by weight of vitamin E acetate
.. 2 parts by weight, 0.5 parts by weight of 1-menthol, 1 part by weight of saffron extract, 55 parts by weight of ethanol, 2 parts by weight of polyoxyethylene (20) polyoxypropylene (6) decyltetradecyl ether, 0 parts by weight of tetrasodium ethetate .0
5 parts by weight of dibutylhydroxytoluene, 0.05 parts by weight of dibutylhydroxytoluene, and 37.9992 parts by weight of purified water were mixed and dissolved to prepare a tonic type hair tonic.
【0014】試験例
実施例2に準じ、表1に示す処方で試料1〜4及び比較
として、保湿効果を有するとされているプロピレングリ
コール、グリセリン、ヒアルロン酸、コンドロイチン硫
酸ナトリウムを配合した処方で試料5〜8を調製した。
試料1〜8について、保湿効果の評価として一般的に採
用されているインピーダンスメーターを用いた方法で保
湿効果の目安となるコンダクタンス(単位:u▲モ−▼
,表2及び表3において同じ)を求めた。試験条件は以
下に示す。
被験者:健常人7名(女性4名、男性3名)塗布部位:
左右上腕部内側、約10cm2 塗布量
:約30mg
測定環境:23+1℃、50+5%RHインピーダンス
メーター:IBS社製Model1B−354型
保湿効果の測定結果を表2及び表3に示した。また、試
料4〜8の結果を図1にあわせて示した。これらの結果
から、サフラン抽出物は従来品より優れており、特に、
保湿効果に持続性がみられる。Test Example According to Example 2, samples 1 to 4 were prepared with the formulation shown in Table 1, and for comparison, samples were prepared with a formulation containing propylene glycol, glycerin, hyaluronic acid, and sodium chondroitin sulfate, which are said to have a moisturizing effect. 5 to 8 were prepared. For samples 1 to 8, the conductance (unit: u▲mo-▼
, the same in Tables 2 and 3) were determined. The test conditions are shown below. Subjects: 7 healthy people (4 women, 3 men) Application site:
Inner left and right upper arms, approximately 10 cm2 Application amount: approximately 30 mg Measurement environment: 23+1°C, 50+5% RH Impedance meter: IBS Model 1B-354 The results of measuring the moisturizing effect are shown in Tables 2 and 3. Moreover, the results of samples 4 to 8 are also shown in FIG. 1. These results show that saffron extract is superior to conventional products, especially
The moisturizing effect is long-lasting.
【0015】[0015]
【表1】[Table 1]
【0016】[0016]
【表2】[Table 2]
【0017】※1 表中の値は平均値±標準偏差を表
す。*1 The values in the table represent the average value ± standard deviation.
【0018】[0018]
【表3】[Table 3]
【0019】※2 表中の値は平均値±標準偏差を表
す。*2 The values in the table represent the average value ± standard deviation.
【図1】本発明のサフラン抽出物含有製剤と市販保湿剤
含有製剤の保湿効果を比較したグラフである。図中、縦
軸は導電率を、横軸は時間を示す。FIG. 1 is a graph comparing the moisturizing effects of a saffron extract-containing preparation of the present invention and a commercially available moisturizing agent-containing preparation. In the figure, the vertical axis represents conductivity, and the horizontal axis represents time.
Claims (1)
外用保湿剤。Claim 1: An external skin moisturizer containing saffron extract as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14701391A JP3607709B2 (en) | 1991-04-02 | 1991-04-02 | Skin moisturizer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14701391A JP3607709B2 (en) | 1991-04-02 | 1991-04-02 | Skin moisturizer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04305519A true JPH04305519A (en) | 1992-10-28 |
JP3607709B2 JP3607709B2 (en) | 2005-01-05 |
Family
ID=15420577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14701391A Expired - Fee Related JP3607709B2 (en) | 1991-04-02 | 1991-04-02 | Skin moisturizer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3607709B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717845A (en) * | 1993-06-30 | 1995-01-20 | Sansho Seiyaku Co Ltd | Skin external preparation |
JPH09124499A (en) * | 1995-09-07 | 1997-05-13 | L'oreal Sa | Extract of sweet flag family and composition containing it |
EP0797985A1 (en) * | 1996-03-27 | 1997-10-01 | L'oreal | Use of an extract of iridaceas in the treatment of skin wrinkles |
CN1098063C (en) * | 1998-08-19 | 2003-01-08 | 上海家化联合股份有限公司 | Sun screening agent and cosmetics containing it |
WO2004056201A1 (en) * | 2002-12-19 | 2004-07-08 | Council Of Scientific And Industrial Research | Method for the preparation of saffron pigment and flavor concentrate |
FR2928835A1 (en) * | 2008-03-20 | 2009-09-25 | Nuxe Soc Par Actions Simplifie | DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. |
JP2015157771A (en) * | 2014-02-21 | 2015-09-03 | 株式会社ナリス化粧品 | cosmetic |
-
1991
- 1991-04-02 JP JP14701391A patent/JP3607709B2/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717845A (en) * | 1993-06-30 | 1995-01-20 | Sansho Seiyaku Co Ltd | Skin external preparation |
JPH09124499A (en) * | 1995-09-07 | 1997-05-13 | L'oreal Sa | Extract of sweet flag family and composition containing it |
EP0797985A1 (en) * | 1996-03-27 | 1997-10-01 | L'oreal | Use of an extract of iridaceas in the treatment of skin wrinkles |
WO1997035556A1 (en) * | 1996-03-27 | 1997-10-02 | L'oreal | Use of an extract of at least one iridaceous plant for treating wrinkles |
FR2746641A1 (en) * | 1996-03-27 | 1997-10-03 | Oreal | USE OF AN EXTRACT OF AT LEAST ONE IRIDACEA IN THE TREATMENT OF WRINKLES |
US6224850B1 (en) | 1996-03-27 | 2001-05-01 | Societe L'oreal S.A. | Antiwrinkle cosmetic/pharmaceutical compositions comprising iridaceae extracts |
CN1098063C (en) * | 1998-08-19 | 2003-01-08 | 上海家化联合股份有限公司 | Sun screening agent and cosmetics containing it |
WO2004056201A1 (en) * | 2002-12-19 | 2004-07-08 | Council Of Scientific And Industrial Research | Method for the preparation of saffron pigment and flavor concentrate |
FR2928835A1 (en) * | 2008-03-20 | 2009-09-25 | Nuxe Soc Par Actions Simplifie | DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. |
WO2009122046A1 (en) * | 2008-03-20 | 2009-10-08 | Laboratoire Nuxe | Crocus sativus depigmenting composition |
JP2015157771A (en) * | 2014-02-21 | 2015-09-03 | 株式会社ナリス化粧品 | cosmetic |
Also Published As
Publication number | Publication date |
---|---|
JP3607709B2 (en) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4252899B2 (en) | Topically applied composition containing multivesicular emulsion and method for producing the same | |
JP3923226B2 (en) | Topical skin preparation | |
JP2764510B2 (en) | Whitening cosmetics | |
JPH04124122A (en) | Blackening agent of preventing gray hair | |
JP2023543917A (en) | Hair, scalp and skin treatment compositions | |
US8715700B2 (en) | Alpha hydroxy acid sustained release formulation | |
JPH04305519A (en) | Skin humectant for external use | |
JPH01199916A (en) | Drug for external use | |
JPH11100324A (en) | Composition for treating pimple | |
JPH0296581A (en) | Biotin ester and skin ointment and hair tonic using the ester | |
JPH11269043A (en) | Cosmetic for scalp and hair | |
JPH11269042A (en) | Cosmetic for scalp and hair | |
JPH09241137A (en) | Hair crowing and restoring agent | |
JPH08133950A (en) | Skin preparation for external use | |
JPH082772B2 (en) | Sebum secretagogue | |
JPH08133948A (en) | Skin preparation for external use | |
KR101322850B1 (en) | The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum | |
JP2004315442A (en) | Gray hair-preventing/improving agent | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
JP3314785B2 (en) | Minoxidil-containing hair restorer | |
JPS63215611A (en) | Cosmetic | |
JPH0692833A (en) | Skin external agent | |
JPH11255621A (en) | Cosmetic for scalp and hair | |
JP2002121108A (en) | Skin care preparation for ameliorating chapped skin | |
JPH0517202B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040716 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041008 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |